You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Financial news, mergers and acquisitions, partnerships, and alliances.
The test has been authorized for use with individual respiratory specimens, as well as with pooled specimens containing up to five samples.
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
The company said it expects core molecular testing revenue between $115 million and $125 million and SARS-CoV-2 revenue between $15 million and $20 million.
Exact Sciences discussed newly released data and its plans for Cologuard, while Luminex provided details about its warning letter from the FDA.
The company said it will use the funding to continue development of its computational technologies, biomarkers, and diagnostics, as well as for new hires.